New drug cocktail aims to shrink untreated lymphoma tumors

NCT ID NCT07585747

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of three drugs (orelabrutinib, tafasitamab, and lenalidomide) as a first treatment for people with follicular lymphoma, a slow-growing blood cancer. The goal is to see how well the drugs shrink tumors and how safe they are. About 27 newly diagnosed adults will take part, and the study is not yet recruiting.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

follicular lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Henan Cancer Hospital

    Zhengzhou, Henan, 450000, China

  • Institute of Hematology & Blood Diseases Hospital, China

    Tianjin, Tianjin Municipality, 300020, China

  • Qilu Hospital of Shandong Province

    Jinan, Shandong, China

    Contact Phone: •••-•••-••••

  • Shenzhen Second People's Hospital

    Shenzhen, Guangdong, China

    Contact Phone: •••-•••-••••

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, 330000, China